Tandem Diabetes Care (Nasdaq:TNDM) announced today that it appointed two new independent members to its board of directors. Myoung Cha and Joao Malagueira have been named to the San Diego-based automated insulin delivery technology developer’s board, effective yesterday. “We welcome Joao and Myoung to our board of directors at this exciting stage in Tandem’s evolution,” […]
Tandem Diabetes Care
The biggest stories from the American Diabetes Association (ADA) 2022 Scientific Sessions
For the 82nd time, the American Diabetes Association (ADA) Scientific Sessions convened to highlight all the innovations within the diabetes technology space. Major players like Dexcom, Medtronic, Abbott, Insulet and more continue to plug along, while companies like Bigfoot Biomedical, One Drop and others shared data backing the technology that they bring to the table. […]
Dexcom CEO expects ‘science boom’ with CGM, automated insulin delivery
With the G7 nearing FDA clearance, Dexcom leadership foresees major innovations for integrated automated insulin delivery down the line. Kevin Sayer began thinking about automated insulin delivery all the way back in 1994 when he was working at MiniMed. Nearly 30 years later, as CEO of Dexcom (Nasdaq:DXCM), that space continues to pique his interest. […]
Tandem reports positive data for t:slim X2 insulin pump with Control-IQ technology
Tandem Diabetes Care (Nasdaq:TNDM) announced today that real-world data supports its t:slim X2 insulin pump with Control-IQ technology. Data from the ongoing real-world Control-IQ observational (CLIO) study demonstrating immediate and sustained benefits in a diverse cohort of participants was presented at the American Diabetes Association (ADA) 82nd Scientific Sessions in New Orleans. “Our Control-IQ technology continues […]
Tandem stock down after Q1 EPS miss
Tandem Diabetes Care (Nasdaq:TNDM) shares are down today, a day after first-quarter results that were mixed compared to the consensus forecast. The San Diego-based automated insulin delivery technology developer posted losses of $14.7 million, or 23¢ per share, on sales of $175.9 million for the three months ended March 31, 2022, for a bottom-line slide […]
CGMs, insulin pumps and more: the biggest diabetes news to come out of ATTD 2022
All kinds of technologies were on display at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona last week. From continuous glucose monitoring (CGM) to automated insulin delivery, with plenty in between, a number of companies shared positive data for their diabetes offerings. Here are five of the biggest stories to come out […]
Real-world evidence shows Tandem’s t:slim X2 insulin pump improves outcomes
Tandem Diabetes Care (Nasdaq:TNDM) announced real-world data confirming positive outcomes with its t:slim X2 insulin pump. Data demonstrated that the t:slim X2 pump with Control-IQ advanced hybrid closed-loop technology resulted in immediate and ongoing improvements in glycemic control, quality of life outcomes and user-reported reduced burden of diabetes management. According to a news release, the […]
Diabetes tech is off to a hot start in 2022
Diabetes tech developers have high hopes for the year ahead, some of which have already come to fruition. Change is continuous in continuous glucose monitoring (GCM), with expanded wear-times, improved accuracy and more. Meanwhile, never-ending innovation in insulin delivery is delivering wearable patches and closedloop delivery systems, making insulin management easier for people with diabetes. […]
Tandem Diabetes warns on some t:slim X2 insulin pumps
Tandem Diabetes Care (Nasdaq:TNDM) issued an urgent field safety notice in Europe for its t:slim X2 insulin pump with Basal-IQ technology. The notice, dated February 2022, alerts users of Tandem’s insulin pump with a software version of 6.3.0.1 that there may be a potential safety risk when using the pump within its normal specifications. Tandem’s […]
Tandem Diabetes Care beats Street on Q4 sales, posts EPS miss
Tandem Diabetes Care (NASDAQ:TNDM) shares were slightly up on fourth-quarter results that beat the consensus revenue forecast. The San Diego-based company posted profits of $10.8 million, or 16¢ per share, on sales of $210 million for the three months ended Dec. 31, 2021, for a 36.4% bottom-line slide on sales growth of 24.9%. Tandem Diabetes […]
